Intro Biosystems wins Disrupt 2026 cup with tests that mimic human gut response to drugs
Listen to this article
Read by Anchor
The judging panels in San Francisco decided the startup platform competition for the “Tech Crunch Disrupt 2026” event by selecting Intro Biosystems as the championship winner, awarding a $100,000 prize. The award came after three days of intensive live pitches in which twenty emerging companies, chosen from two hundred applicants, competed before bold investors and technology leaders who tipped the decision in favor of promising biotech.
The winning company is based in Denver and was founded by Charlie Childs and Madeline Aiken, stemming from university research at the University of Michigan in the United States. Intro Biosystems develops laboratory-grown human intestinal tissue one millimeter in size that mimics real gut, giving labs a practical tool to study the effects of drugs and chemical compounds on the human body before reaching clinical trials in humans. The company sells its flagship product, GastroScreen, to pharmaceutical and biotech firms as well as food and chemical companies for compound testing and reducing early-stage error margins.
The judging panel favored precise biological modeling over software-agent solutions in the final round.The final shortlist comprised five qualified companies: Abati, Flux Intelligence, Intro Biosystems, Industrial Next, and Satellite, and their pitches were heard by judges representing venture funds such as Inspired Capital, Good Water Capital, Construct Capital, M13, and Shire Rock Capital. The Australian firm Abati placed second; it was founded by Dali Kafar of Macquarie University in Sydney and deploys thousands of smart agents that masquerade as victims to answer phishing calls and spoofed messages, luring fraudsters and providing organizations with proactive security analytics.
Intro Biosystems' and Abati's inclusion among the winners puts them on a historic trajectory that previously featured platforms such as Discord, Cloudflare, Trello, and Mint. Competition records show that over 1,700 companies have participated over its history, raising more than $30 billion in funding and logging over two hundred successful exits, making this win an investment signal of capital moving toward technologies that address deep material challenges in production and development chains.
Turning bio-tissue tests into validated commercial models reshapes the cost equation for regional labs and drug manufacturers.This development enables drug R&D teams in Saudi Arabia, the United Arab Emirates, and Egypt to bypass traditional bottlenecks in toxicity testing and intestinal response to compounds; using human-organ-mimicking tissues provides early inference data that reduces costly clinical trial failures. With the region's push to localize biopharma manufacturing and inject strategic investments into genetic science, adopting platforms such as GastroScreen becomes a cost-saving alternative for field trials and speeds the preparation of regulatory dossiers. In parallel on the security front, Abati's defensive-agent model imposes a new capability on cyber-protection teams at banks and regional telecom firms, prompting a shift from passive firewalls to deploying smart agents that drain fraud-network resources and collect attack evidence early.
The competition results reveal that the current stage gives priority to solutions able to bridge the gap between biological data and tangible industrial applications. Competition is no longer limited to dazzling presentations; the real gamble now rests on tools that lower experimental risk and withstand strict verification standards in real-world labs and markets.